UA group
Dietary SupplementUrsolic Acid of Loquat Extract, 500mg/ day during 12 weeks
NCT Number: NCT02401113
This randomized, placebo-controlled, double-blind study was designed to investigate the efficacy and tolerability of Ursolic Acid of Loquat Extract for treatment of muscle function improvement with relatively health adults. 54 subjects received 500 mg of Loquat Extract per day or a placebo for 12 weeks.
Looking for future studies?
Notify Me19 year–65 year
All sexes
Interventional
Phase 2 / Phase 3
This randomized, placebo-controlled, double-blind study was designed to investigate the efficacy and tolerability of Ursolic Acid of Loquat Extract for treatment of muscle function improvement with relatively health adults. 54 subjects received 500 mg of Loquat Extract per day or a placebo for 12 weeks. Change over time in muscle fuction was evaluated by four outcomes: assessment of appendicular skeletal mass using DEXA (dual energy X-ray absorptiometry); quadriceps muscle power by Biodex; hand grib power; and Short Physical Performance Battery, SPPB.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ursolic Acid of Loquat Extract, 500mg/ day during 12 weeks
Time frame: 12weeks
Time frame: 12weeks
Time frame: 12weeks
Pusan National University Hospital
Other
Effect of Ursolic Acid of Loquat Extract on Function of Muscle in Human
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07580144
Atrophy, Frailty
Konya, Turkey (Türkiye)
View Trial DetailsNCT06629805
Atrophy, Muscular Atrophy
Yangsan, South Korea
View Trial DetailsNCT07629063
Atrophy, Basal Ganglia Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07716839
Aging, Atrophy
Montes Claros, Minas Gerais, Brazil
View Trial Details